A phase I/II safety, tolerability and 'proof of concept' study of radiotherapy, cetuximab, and intratumoral injections of TNFerade [tumour necrosis factor-alpha gene therapy] biologic (AdGVEGR.TNF.11D) for elderly or frail patients with head and neck cancer

Trial Profile

A phase I/II safety, tolerability and 'proof of concept' study of radiotherapy, cetuximab, and intratumoral injections of TNFerade [tumour necrosis factor-alpha gene therapy] biologic (AdGVEGR.TNF.11D) for elderly or frail patients with head and neck cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs Golnerminogene pradenovec (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms TNF-ELF
  • Sponsors GenVec
  • Most Recent Events

    • 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 31 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top